Last reviewed · How we verify
Levemir twice a day
At a glance
| Generic name | Levemir twice a day |
|---|---|
| Sponsor | Rabin Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Closed Loop From Onset in Type 1 Diabetes (NA)
- Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes (PHASE3)
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin (PHASE4)
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (PHASE4)
- Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM (NA)
- The REPOSE (Relative Effectiveness of Pumps Over MDI and Structured Education) Trial (PHASE3)
- Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120) (PHASE2)
- The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levemir twice a day CI brief — competitive landscape report
- Levemir twice a day updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI